Empagliflozin for advanced kidney disease in type 2 diabetes
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes.
- You are between 18 and 80 years old.
- Your kidney function (eGFR) is between 10 and 20 – this is very low, often called 'severe kidney disease'.
- You are already taking a blood pressure medication from the ACE inhibitor or ARB group (like lisinopril or losartan) at the highest dose you can tolerate, for at least 1 month.
- Your urine shows a high amount of protein (higher than 300 mg/g on a spot check).
- If you are a woman who could become pregnant, you must use effective birth control for at least 1 month before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This study is testing whether the drug empagliflozin (Jardiance) can help protect the kidneys of African American veterans who already have some kidney damage but do not have diabetes. The goal is to see if the drug can reduce damage at the cellular level.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.